Summit Therapeutics-Spon ADRSMMT

13F holders, Q2 2025 (June 30)
12holders +2
6new positions
3sold out
$21.28avg. 13F price*

At the end of Q2 2025, 12 institutions reported holding Summit Therapeutics-Spon ADR (SMMT) in their 13F filings, up 2 from Q1 2025. 6 opened new positions and 3 sold out. The largest holders were Parallel Advisors, LLC ($43K), Farther Finance Advisors, LLC ($12K) and Rosenberg Matthew Hamilton ($11K).

Company
Summit Therapeutics-Spon ADR
CUSIP
86627R102
Latest filing quarter
Q2 2025

History

Number of 13F holders

051015 Q1 2024: 2Q1 2024Q2 2024: 2Q2 2024Q3 2024: 2Q3 2024Q4 2024: 7Q4 2024Q1 2025: 10Q1 2025Q2 2025: 12Q2 2025

Total Exit/New Position Q1 2025 → Q2 2025

InstitutionsTotal Value
New Positions6$17K
Exits3$5K

All 13F filers, Q1 2025 → Q2 2025: 2,828 shares bought and 474 shares sold, net +2,354 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.

Ownership 12 holders

Parallel Advisors, LLC 0.00% Add +10647.4% 2,042 $43K
Farther Finance Advisors, LLC 0.00% Reduce -14.4% 560 $12K
Rosenberg Matthew Hamilton 0.00% New 501 $11K
EverSource Wealth Advisors, LLC 0.00% Reduce -18.3% 370 $8K
Roxbury Financial LLC 0.00% New 187 $4K
Park Place Capital Corp 0.00% New 62 $1K
Sierra Ocean, LLC 0.00% New 38 $809
Rise Advisors, LLC 0.00% Reduce -49.1% 28 $596
AdvisorNet Financial, Inc 0.00% No change 22 $468
Fortitude Family Office, LLC 0.00% New 15 $319
Bay Harbor Wealth Management, LLC 0.00% Add +25.0% 5 $106
Twin Peaks Wealth Advisors, LLC 0.00% New 1 $26

"% of holder's portfolio" is SMMT's weight in each manager's 13F, not the share of Summit Therapeutics-Spon ADR the manager owns.